345 related articles for article (PubMed ID: 16223773)
1. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
Zemann B; Kinzel B; Müller M; Reuschel R; Mechtcheriakova D; Urtz N; Bornancin F; Baumruker T; Billich A
Blood; 2006 Feb; 107(4):1454-8. PubMed ID: 16223773
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.
Kharel Y; Lee S; Snyder AH; Sheasley-O'neill SL; Morris MA; Setiady Y; Zhu R; Zigler MA; Burcin TL; Ley K; Tung KS; Engelhard VH; Macdonald TL; Pearson-White S; Lynch KR
J Biol Chem; 2005 Nov; 280(44):36865-72. PubMed ID: 16093248
[TBL] [Abstract][Full Text] [Related]
3. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
Paugh SW; Payne SG; Barbour SE; Milstien S; Spiegel S
FEBS Lett; 2003 Nov; 554(1-2):189-93. PubMed ID: 14596938
[TBL] [Abstract][Full Text] [Related]
4. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Don AS; Martinez-Lamenca C; Webb WR; Proia RL; Roberts E; Rosen H
J Biol Chem; 2007 May; 282(21):15833-42. PubMed ID: 17400555
[TBL] [Abstract][Full Text] [Related]
5. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.
Allende ML; Sasaki T; Kawai H; Olivera A; Mi Y; van Echten-Deckert G; Hajdu R; Rosenbach M; Keohane CA; Mandala S; Spiegel S; Proia RL
J Biol Chem; 2004 Dec; 279(50):52487-92. PubMed ID: 15459201
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.
Billich A; Bornancin F; Dévay P; Mechtcheriakova D; Urtz N; Baumruker T
J Biol Chem; 2003 Nov; 278(48):47408-15. PubMed ID: 13129923
[TBL] [Abstract][Full Text] [Related]
7. FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Vessey DA; Li L; Imhof I; Honbo N; Karliner JS
Med Sci Monit Basic Res; 2013 Apr; 19():126-32. PubMed ID: 23567658
[TBL] [Abstract][Full Text] [Related]
8. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
10. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
[TBL] [Abstract][Full Text] [Related]
11. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
13. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
14. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection.
Kraft P; Göb E; Schuhmann MK; Göbel K; Deppermann C; Thielmann I; Herrmann AM; Lorenz K; Brede M; Stoll G; Meuth SG; Nieswandt B; Pfeilschifter W; Kleinschnitz C
Stroke; 2013 Nov; 44(11):3202-10. PubMed ID: 24029635
[TBL] [Abstract][Full Text] [Related]
15. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
Sawicka E; Dubois G; Jarai G; Edwards M; Thomas M; Nicholls A; Albert R; Newson C; Brinkmann V; Walker C
J Immunol; 2005 Dec; 175(12):7973-80. PubMed ID: 16339533
[TBL] [Abstract][Full Text] [Related]
16. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A; Igarashi Y
Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.
Sanchez T; Estrada-Hernandez T; Paik JH; Wu MT; Venkataraman K; Brinkmann V; Claffey K; Hla T
J Biol Chem; 2003 Nov; 278(47):47281-90. PubMed ID: 12954648
[TBL] [Abstract][Full Text] [Related]
18. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.
Foss FW; Mathews TP; Kharel Y; Kennedy PC; Snyder AH; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem; 2009 Aug; 17(16):6123-36. PubMed ID: 19632123
[TBL] [Abstract][Full Text] [Related]
20. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Hait NC; Wise LE; Allegood JC; O'Brien M; Avni D; Reeves TM; Knapp PE; Lu J; Luo C; Miles MF; Milstien S; Lichtman AH; Spiegel S
Nat Neurosci; 2014 Jul; 17(7):971-80. PubMed ID: 24859201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]